Get the Stockscreener App
132.21
0.25%
-0.39
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $132.21, with a volume of 1.63M.
It is down -0.25% in the last 24 hours and up +6.29% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$132.60
Open:
$131.95
24h Volume:
1.63M
Relative Volume:
0.24
Market Cap:
$224.65B
Revenue:
$42.34B
Net Income/Loss:
$13.50B
P/E Ratio:
17.15
EPS:
7.71
Net Cash Flow:
$6.66B
1W Performance:
+1.36%
1M Performance:
+6.29%
6M Performance:
+13.24%
1Y Performance:
+25.21%
1-Day Range:
$130.70
$132.57
1-Week Range:
$128.00
$136.80
52-Week Range:
$99.71
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
132.18 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.09 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
378.58 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
82.62 | 107.01B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
74.89 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Judge throws out case against Abbott over preterm baby formulas - Chicago Tribune
One of Abbott's first federal baby formula lawsuits dismissed - Crain's Chicago Business
Abbott Beats Bellwether Formula MDL Trial in Federal Court Ruling - USA Herald
Judge throws out case against Abbott Laboratories over its preterm baby formula, days before trial was set to begin in Chicago - Yahoo
Positive Legal and Market Factors Justify Buy Rating for Abbott Laboratories - TipRanks
Judge Allows Testimony That Abbott, Mead Johnson Baby Formula Caused Disease - Insurance Journal
Winnetka crash: Raziyeh Sigary, Sediqeh Samadi identified as pedestrians killed at Church Road, Meadow Road; infant injured - ABC7 Chicago
Abbott (ABT) Launches Rapid Concussion Test with MotoAmerica - GuruFocus
Abbott Nutrition Reaches Deal With FDA To Reopen Baby Formula Plant Amid Shortage - Class Action Lawsuits
2 Stocks, 2 Decades, $200. Is This the Long-Term Dividend Play for Your Portfolio? - The Motley Fool
Abbott Laboratories Director Makes Significant Stock Sale! - TipRanks
Abbott Beats Bellwether In Formula MDL Ahead Of Trial - Law360
US judge allows testimony that Abbott and Mead Johnson preterm baby formula caused deadly disease - Reuters
Abbott Laboratories (ABT) Sees Stock Rise Following Favorable Court Ruling - GuruFocus
Abbott gains after upcoming baby formula case thrown out (ABT:NYSE) - Seeking Alpha
Abbott Laboratories First Quarter 2025 Earnings: EPS Misses Expectations - simplywall.st
Stroke Management Market Is Booming Worldwide | Abbott - openPR.com
Investors in Abbott Laboratories (NYSE:ABT) have seen notable returns of 52% over the past five years - Yahoo Finance
Abbott Laboratories Announces Executive Vice President’s Retirement - TipRanks
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races - Yahoo Finance
Abbott Laboratories (ABT): Among the Best Stocks to Buy During Recession - Yahoo Finance
Abbott Laboratories price tries to shake off negative pressureForecast today01-05-2025 - Economies.com
MotoAmerica: More On Abbott Blood Test for Rapid Concussion Evaluation On-Site - Roadracing World
Abbott Laboratories (ABT): Jim Cramer Calls It a ‘Tour de Force’ — Why He’s Still Amazed at This Stock - Yahoo Finance
Abbott Laboratories (ABT) Announces Results of Annual Shareholders Meeting - GuruFocus
Abbott (ABT) Integrates Libre CGM Data with Epic's Health Records - GuruFocus
Abbott signs deal with Epic for CGM data integration (ABT:NYSE) - Seeking Alpha
Abbott Integrates Libre CGM’s Data with Epic’s EHR System - Medical Product Outsourcing
Abbott (ABT) Teams Up with Epic for Advanced Health Data Integra - GuruFocus
Abbott integrates Libre CGM data into Epic EHR workflows - Drug Delivery Business
Abbott Partners With Epic to Transform Diabetes Care for 280M Patients | ABT Stock News - Stock Titan
Sevoflurane Market Overall Study Report 2025-2032 | Abbott Laboratories, Baxter, Piramal Pharma Solutions - openPR.com
A Look Into Abbott Laboratories Inc's Price Over Earnings - Benzinga
Abbott Laboratories (NYSE:ABT) Unveils Breakthrough Leadless Pacemaker Advances In New Clinical Trials - simplywall.st
3 Dividend Stocks to Buy and Hold for the Next Decade - Yahoo Finance
Abbott (ABT) Unveils Promising Results from Leadless Pacemaker S - GuruFocus
The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic - Yahoo Finance
Drug Eluting Stents Market Overall Study Report 2025-2032 | - openPR.com
Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price - Yahoo Finance
Abbott Laboratories Insiders Sold US$3.3m Of Shares Suggesting Hesitancy - simplywall.st
The health care sector is a mixed picture, but Abbott Labs is a buy. - Forbes
Abbott Stuns with Study Results in PFA Market: Is It Enough? - Medical Device and Diagnostic industry
Pesticides Market to Experience Rapid Growth Driven by Abbott - openPR.com
Abbott Laboratories Says Investigational Pacemaker Shows Safety, Performance - marketscreener.com
India Medical Nutrition Market Overall Study Report 2025-2032 | - openPR.com
Abbott has positive study results for Aveir CSP leadless pacemaker - MassDevice
Abbott Laboratories: Strategic Advancements and Market Positioning with Volt PFA Platform Drive Buy Rating - TipRanks
Abbott announces new data from its Volt CE Mark Study - TipRanks
Breakthrough Heart Technology: Abbott's Leadless Pacemaker Trial Success Launches Major Global Study - Stock Titan
New data supports Abbott Volt pulsed field ablation system - MassDevice
Abbott Laboratories Says New Clinical Study Data Showcase Long-Term, Sustained Benefits Of Abbott's Volt(TM) Pfa System For Patients With Afib - marketscreener.com
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.12%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):